12:00 AM
 | 
Nov 14, 2011
 |  BioCentury  |  Finance

Mpex reprise

Antibiotics play Rempex, a spinout of Mpex assets, raises $67.5M B round
Mpex reprise

Antibiotics spinout Rempex Pharmaceuticals Inc. came out of stealth mode last week with a series B round of up to $67.5 million.

New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences (SVLS); OrbiMed Advisors; and Adams Street Partners.

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >